Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases

Life Sci. 2023 Apr 15:319:121531. doi: 10.1016/j.lfs.2023.121531. Epub 2023 Feb 27.

Abstract

SARS-CoV-2 virus has attracted a lot of attention globally due to the autoimmune and inflammatory processes that were observed during the development of Covid-19 disease. Excessive activation of immune response and triggering of autoantibodies synthesis as well as an excessive synthesis of inflammatory cytokines and the onset of cytokine storm has a vital role in the disease outcome and the occurring autoimmune complications. This scenario is reminiscent of infiltration of lymphocytes and monocytes in specific organs and the increased production of autoantibodies and chemoattractants noted in other inflammatory and autoimmune diseases. The main goal of this study is to investigate the complex inflammatory processes that occur in Covid-19 disease and to find similarities with other inflammatory diseases such as multiple sclerosis (MS), acute respiratory distress syndrome (ARDS), rheumatoid arthritis (RA) and Kawasaki syndrome to advance existing diagnostic and therapeutic protocols. The therapy with Interferon-gamma (IFN-γ) and the use of S1P receptor modulators showed promising results. However, there are many unknowns about these mechanisms and possible novel therapies. Therefore, the inflammation and autoimmunity triggered by Covid-19 should be further investigated to improve existing diagnostic procedures and therapeutic protocols for Covid-19.

Keywords: Autoimmune diseases; B-cell tolerance and T-cell tolerance; Covid-19; Cytokine storm; Immunological reaction; Inflammatory reaction; Therapeutic protocols.

Publication types

  • Review

MeSH terms

  • Autoantibodies
  • Autoimmune Diseases* / complications
  • Autoimmune Diseases* / drug therapy
  • COVID-19* / complications
  • Cytokines
  • Humans
  • Inflammation
  • SARS-CoV-2

Substances

  • Cytokines
  • Autoantibodies